SNGX
Soligenix, Inc. Common Stock
stockNASDAQ
soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.36 | 2026-10-05 | -1.73% | 4.459 |
| 1M | 0.36 | 2026-09-11 | -3.08% | 1.480 |
| 6M | 1.15 | 2026-04-13 | -69.32% | 2.361 |
| 1Y | 1.72 | 2025-10-13 | -79.49% | 2.116 |
| 2Y | 3.90 | 2024-10-11 | -90.95% | — |
| 5Y | 251.75 | 2021-10-12 | -99.86% | 0.587 |
Soligenix, Inc. Common Stock (NASDAQ:SNGX) stock price today is $0.35, and today's volume is 58,023. SNGX is down 2.970% today. The 30 day average volume is 205,466. SNGX market cap is $7.68M with 21.77M shares outstanding.